 Mass High Tech | Biogen Idec Q1 revenues up 7 percent Mass High Tech ... has announced that its first-quarter revenues for the three months ending on March 31 were $1.3 billion, up 7 percent from the same time a year before, due largely to increased sales of the drugs Tysabri (natalizumab) and Rituxan (rituximab). Biogen Idec Increases Revenue 7% to $1.3 Billion in the First Quarter Biogen Idec's CEO Discusses Q1 2012 Results - Earnings Call Transcript |
